Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.20.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Feb. 06, 2019
Jan. 30, 2018
Aug. 20, 2007
Mar. 31, 2020
Mar. 31, 2019
Commitments and Contingencies (Textual)          
Rent expense $ 13,800        
Description of settlement agreement The Company entered into a settlement agreement in its previous dispute with Najib Babul, Relmada's former President. Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. The Company recorded a loss on the settlement of $1.1 million in the first quarter of 2019.        
Recognized lease expense       $ 41,600 $ 23,200
Recognized lease income       4,900 $ 6,300
Licensing Agreements [Member]          
Commitments and Contingencies (Textual)          
Rent expense       $ 7,500  
Lease term, description       The Company's leases consist of one lease for their corporate headquarters, which is for a period of 12 months or less. In accordance with ASU 2016-02, Leases, the Company has elected the practical expedient and recognizes rent expense evenly over the 12 months.  
Lease expiration date       Dec. 31, 2019  
Amount of monthly rent       $ 13,800  
Leases and Sublease, description       The Company entered into an Amended and Restated License Agreement with Actinium. Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of March 31, 2020, the balance of unearned interest income was approximately $27,200.  
Licensing Agreements [Member]          
Commitments and Contingencies (Textual)          
Description of rights granted to license agreement   In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.      
Licensing Agreements [Member] | Wonpung [Member]          
Commitments and Contingencies (Textual)          
Lease term, description     The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory.    
Upfront license fee     $ 1,500,000    
Business acquisition, description       (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of March 31, 2020, the Company has not generated any revenue related to this license agreement.  
Net sales rate     12.00%